Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||MAGE-A1-specific TCR cells + unspecified PD-1 antibody|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MAGE-A1-specific TCR cells||MAGE-A1-specific TCR-transduced autologous T cells||MAGE-A1-specific TCR cells consist of autologous T-lymphocytes that are engineered to express a T-cell receptor that recognizes the human melanoma antigen 1 (MAGE-A1), which potentially inhibits growth of MAGE-A1-expressing tumor cells (NCI Drug Dictionary).|
|unspecified PD-1 antibody||Experimental PD-1 antibody||Immune Checkpoint Inhibitor 155 PD-L1/PD-1 antibody 105|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04639245||Phase Ib/II||MAGE-A1-specific TCR cells + unspecified PD-1 antibody Cyclophosphamide + Fludarabine Atezolizumab + MAGE-A1-specific TCR cells MAGE-A1-specific TCR cells||Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer||Terminated||USA||0|